Mn Services Vermogensbeheer B.V. Has $26.01 Million Position in Zoetis Inc. $ZTS

Key Points

• Mn Services Vermogensbeheer B.V. reduced its stock position in Zoetis Inc. by 1.9%, now holding 166,803 shares valued at approximately $26 million following the sale of 3,200 shares in the second quarter.
• Several institutional investors have recently increased their stakes in Zoetis, including a significant increase of over 4,158% by Mackenzie Financial Corp.
• Zoetis reported earnings of $1.76 per share for the last quarter, surpassing analysts' expectations and showing a revenue increase of 4.2% year-over-year, with guided EPS for FY 2025 set between 6.300 and 6.400.

Mn Services Vermogensbeheer B.V. reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 166,803 shares of the company's stock after selling 3,200 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Zoetis were worth $26,013,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis in the first quarter worth $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC raised its position in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS traded down $1.28 during trading hours on Friday, hitting $145.82. 4,455,824 shares of the stock were exchanged, compared to its average volume of 2,273,605. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm's fifty day moving average price is $151.25 and its 200 day moving average price is $156.59. The company has a market cap of $64.63 billion, a P/E ratio of 25.10, a P/E/G ratio of 2.36 and a beta of 0.89. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same period last year, the firm earned $1.56 earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Argus reaffirmed a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.